Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrik Lassen

Showing results (31-40 of 159) with videos related to

Pageof 16
Sort By:
Clinical Case Reports|March 9, 2019
Extracranial metastases in glioblastoma-Two case storiesDorte Schou Nørøxe, Signe Regner Michaelsen, Helle Broholm, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2015
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3Morten Mau-Sørensen, Christian Dittrich, Rodrigo Dienstmann, et al.
Journal of Neuro-Oncology|January 7, 2018
Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survivalSigne Regner Michaelsen, Thomas Urup, Lars Rønn Olsen, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|July 22, 2014
Personalized oncology: genomic screening in phase 1Ida Viller Tuxen, Lars Jønson, Eric Santoni-Rugiu, et al.
Acta Oncologica (Stockholm, Sweden)|November 26, 2008
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumoursHans Skovgaard Poulsen, Kirsten Grunnet, Morten Sorensen, et al.
The American Journal of Managed Care|February 24, 2022
Diagnosis and management of TRK fusion cancerShivaani Kummar, Antoine Italiano, Marcia S Brose, et al.
Lung Cancer (Amsterdam, Netherlands)|November 27, 2007
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trialMorten Sorensen, Ulrik Lassen, Torben Palshof, et al.
The American Journal of Managed Care|February 24, 2022
Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancerJosh J Carlson, Antoine Italiano, Marcia S Brose, et al.
Acta Oncologica (Stockholm, Sweden)|May 3, 2012
A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapySøren Møller, Kirsten Grunnet, Steinbjørn Hansen, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 5, 2024
Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumabChristina Jensen, Simone Maarup, Hans Skovgaard Poulsen, et al.
Pageof 16

Showing results (31-40 of 159) with videos related to

Sort By:
Pageof 16
Clinical Case Reports|March 9, 2019
Extracranial metastases in glioblastoma-Two case storiesDorte Schou Nørøxe, Signe Regner Michaelsen, Helle Broholm, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2015
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3Morten Mau-Sørensen, Christian Dittrich, Rodrigo Dienstmann, et al.
Journal of Neuro-Oncology|January 7, 2018
Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survivalSigne Regner Michaelsen, Thomas Urup, Lars Rønn Olsen, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|July 22, 2014
Personalized oncology: genomic screening in phase 1Ida Viller Tuxen, Lars Jønson, Eric Santoni-Rugiu, et al.
Acta Oncologica (Stockholm, Sweden)|November 26, 2008
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumoursHans Skovgaard Poulsen, Kirsten Grunnet, Morten Sorensen, et al.
The American Journal of Managed Care|February 24, 2022
Diagnosis and management of TRK fusion cancerShivaani Kummar, Antoine Italiano, Marcia S Brose, et al.
Lung Cancer (Amsterdam, Netherlands)|November 27, 2007
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trialMorten Sorensen, Ulrik Lassen, Torben Palshof, et al.
The American Journal of Managed Care|February 24, 2022
Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancerJosh J Carlson, Antoine Italiano, Marcia S Brose, et al.
Acta Oncologica (Stockholm, Sweden)|May 3, 2012
A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapySøren Møller, Kirsten Grunnet, Steinbjørn Hansen, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 5, 2024
Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumabChristina Jensen, Simone Maarup, Hans Skovgaard Poulsen, et al.
Pageof 16